Clinical Trials
31
4 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
Active, not recruiting
4
12.9%
Completed
19
61.3%
Recruiting
3
9.7%
Terminated
5
16.1%
No approval data available
- The global molecular diagnostics market is projected to grow from USD 19.48 billion in 2025 to USD 30.74 billion by 2030, at a CAGR of 9.6%, according to MarketsandMarkets. - PCR and real-time PCR technologies dominate the market with a 42.54% revenue share, while sequencing-based testing is the fastest-growing segment due to personalized medicine adoption. - North America leads the global market with a 38.49% share, while Asia Pacific is the fastest-growing region with an estimated CAGR of 24.45% through 2035. - Key players including Roche, Danaher, Abbott, and Thermo Fisher are investing in automation, AI-powered analytics, and multiplex assay development to strengthen competitive positioning.
- Abbott Laboratories reported FY 2025 revenue of nearly $44.3 billion with a net margin of approximately 14.7%, while completing its acquisition of Exact Sciences to expand into cancer diagnostics. - Intuitive Surgical achieved FY 2025 revenue close to $10.1 billion, representing approximately 20.5% growth, with a net margin of nearly 28.4% and a debt-free balance sheet. - Abbott faces headwinds including product liability exposure, $20 billion in acquisition-related debt, and FDA regulatory scrutiny, while Intuitive Surgical confronts tariff impacts and increasing RAS market competition. - Both companies remain leaders in their respective niches, with Abbott offering diversified stability and dividends versus Intuitive Surgical's high-growth, razor-and-blades recurring revenue model.
